HH
Hsing-Pang Hsieh
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, National Tsing Hua University, State University of New York, National Health Research Institutes
Research areas: Chemistry · Organic Chemistry · Synthesis and biological activity · Computational Drug Discovery Methods · Microtubule and mitosis dynamics
0000-0002-1332-005X
Employment
-
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes Associate Director2015 - Present
- 2012 - 2014
- 2009 - 2012
-
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes Investigator2007 - Present
-
Department of Chemistry, National Tsing Hua University Adjunct Professor2007 - Present
- 2007 - 2009
-
National Health Research Institutes Institute of Biotechnology and Pharmaceutical Research Associate Investigator2003 - 2007
-
Shionogi BioResearch Corp. Visiting Scholar1999 - 1999
-
National Health Research Institutes Institute of Biotechnology and Pharmaceutical Research Assistant Investigator1998 - 2002
-
Institute of Biological Chemistry Academia Sinica Post-Doctoral Fellow1997 - 1998
-
Department of Chemistry, Boston College Research Associate1994 - 1995
Education
- ? - 1993
- ? - 1987
- ? - 1985
Projects & Funding
Projects & funding information is unavailable.
Publications (212)
- Asymmetric total synthesis of C2-OH lycopodium alkaloids (-)-palhinine B, (-)-palhinine C, and (+)-palhinine B enabled by stereocontrolled diels-alder strategy Save
- Development of a practical and scalable synthetic route for DBPR112: A clinical candidate for the treatment of non-small cell lung cancer Save
- Isorhoifolin regulates S1PR3-CK2-GSK3β axis and promotes neurite regrowth and functional recovery after traumatic brain injury Save
- Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models Save
- Aldehyde dehydrogenases as drug targets for cancer: SAR and structural biology aspects for inhibitor design Save
- Identification and biological evaluation of a novel CLK4 inhibitor targeting alternative splicing in pancreatic cancer using structure-based virtual screening Save
- Integrating machine learning and protein-ligand interaction profiling for the discovery of METTL3 inhibitors Save
- KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules Save
- Noncovalent interaction effects on the acyl radical reaction of bicyclo 2.2.2 octanone: Selective formation of rearrangement and cyclization products Save
- Structure-based design of potent and selective merTK inhibitors by modulating the conformation of alphaC helix Save
- Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer Save
- DBPR116, a prodrug of BPRMU191, in combination with naltrexone as a safer opioid analgesic than morphine via peripheral administration Save
- Discovery of DYRK1A inhibitors as potential treatment of pancreatic ductal adenocarcinoma (PDAC) Save
- Discovery of dual MER/AXL kinase inhibitors as bifunctional small molecules for inhibiting tumor growth and enhancing tumor immune microenvironment Save
- Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma Save
- Macrophage-mediated controlled release of cysteine protease inhibitor from PLGA-PEG/hydroxyapatite microspheres for targeting cathepsin S in Alzheimer's disease Save
- Novel naphthyridones targeting pannexin 1 for colitis management Save
- Targeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function Save
- A dual nociceptin and mu opioid receptor agonist exhibited robust antinociceptive effect with decreased side effects Save
- Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs Save